Lpl Financial LLC T Scan Therapeutics, Inc. Transaction History

Lpl Financial LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$1.66 - $3.32 $8,300 - $16,600	-5,000 Reduced 29.41%	12,000 $25,000
Q4 2022 Feb 07, 2023	BUY	$1.49 - $3.33 $2,980 - $6,660	2,000 Added 13.33%	17,000 $26,000
Q3 2022 Nov 14, 2022	SELL	$2.62 - $4.39 $2,620 - $4,390	-1,000 Reduced 6.25%	15,000 $46,000
Q2 2022 Aug 12, 2022	BUY	$1.65 - $3.58 $26,400 - $57,280	16,000 New	16,000 $50,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.4 $36,400 - $70,200	-13,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.5 - $9.05 $58,500 - $117,650	13,000 New	13,000 $59,000

41.8M

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $58.3M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.